Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LB-102 PET Receptor Occupancy Study in Healthy Volunteers
NCT04588129Phase 1Completed
- Sponsor
- LB Pharmaceuticals
- Start
- Jan 2021
- Primary completion
- Sep 2021
- Modality
- T-cell Engagers, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of LP-102 in schizophrenia (4 arms), sponsored by LB Pharmaceuticals. Primary endpoint: Brain Receptor Occupancy as Measured by Positron Emission Tomography at 23.5 hours. Started Jan 2021; status: completed.
02
Drugs
LP-102
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT04588129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04588129.